# An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

> **NCT01833039** · — · APPROVED_FOR_MARKETING · sponsor: **Janssen Biotech, Inc.**

## Conditions studied

- Relapsed or Refractory Mantle Cell Lymphoma

## Interventions

- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT01833039
- **Lead sponsor:** Janssen Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01833039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01833039, "An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT01833039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*